Journal
PHARMACOGENOMICS
Volume 14, Issue 3, Pages 249-260Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.12.206
Keywords
ACE I/D; ACEI; angioedema; cough; meta-analysis
Categories
Funding
- The Netherlands Organisation for Health Research and Development [90700342]
- Dutch Health Care Insurance Board
- Royal Dutch Pharmacists Association
- EU Innovative Medicines Initiative
- Dutch Medicines Evaluation Board
- Dutch Ministry of Health and Industry
- GlaxoSmithKline
- Pfizer
Ask authors/readers for more resources
Aim: Angioedema and cough are the two most important adverse effects of ACE inhibitors (ACEIs). Evidence exists that ACEI-related angioedema/cough is partly genetically determined and several genes have been identified to play a role in the development of ACEI-related adverse effects. Materials & methods: This study was performed in order to evaluate the evidence of these genetic associations and ACEIs' adverse effects. After removing duplicates and critical appraisal, 19 studies were considered to be eligible to review; 14 articles about cough and five articles about angioedema. A separate meta-analysis was performed for the most studied ACE insertion/deletion polymorphism (rs4646994) and its association with cough. Results & conclusion: One gene region (XPNPEP2) was associated with ACEI-induced angioedema in three studies. In our meta-analysis we did not find a significant association between the ACE insertion/deletion polymorphism and ACEI cough.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available